Daklinza (daclatasvir) / BMS - LARVOL DELTA

Antifibrotic Efficacy of Daclatasvir Against Pulmonary Fibrosis: Insights From Network Pharmacology, Molecular Docking, Dynamics, and Preclinical Evaluations. (PubMed, Chem Biodivers) - "The present study evaluated DAC in a bleomycin (BLM)-induced PF rat model, integrating network pharmacology, molecular docking, and molecular dynamics (MD) simulation to decipher its mechanisms...PCA analyses also confirmed complex stability, comparable to known inhibitors vorinostat and mocetinostat...Interestingly, a higher dose (12.4 mg/kg/day) showed reduced efficacy and increased lung index, indicating dose sensitivity. These findings suggest that DAC possesses dose-dependent antifibrotic activity in PF and warrants further exploration as a repurposable therapeutic candidate."

Journal • Preclinical • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • HDAC2 • HIF1A

In silico screening of potential FGF2 inhibitors for cancer therapy. (PubMed, In Silico Pharmacol) - "Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2."

Journal • Acute Myelogenous Leukemia • Brain Cancer • Breast Cancer • Gastric Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FGF2 • FGFR

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023. (PubMed, J Viral Hepat) - "Viraemic patients were treated with 12- or 24-week regimens of sofosbuvir (400 mg) and daclatasvir (60 mg), depending on the fibrosis degree. The model appears feasible in terms of patient-level outcomes, though broader operational feasibility-including resources and scalability-was not formally assessed. Remaining barriers to treatment initiation and follow-up need to be addressed to advance national HCV elimination goals."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma. (PubMed, Cell Death Differ) - "Notably, high-throughput screening of FDA-approved drugs reveals that Daclatasvir (DCV) exhibits high binding affinity for PSMD14 protein, disrupts the PSMD14-PFKFB2 interaction, reduces PFKFB2 activity and tumor burden. Collectively, our findings are the first to elucidate a positive feedback loop existing between PSMD14 and glycolysis in GAC progression, suggesting that PSMD14 blockade may represent a potential therapeutic approach for GAC."

Journal • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • PSMD14 • SOX9

Analysis of genetic polymorphisms and drug resistance mutations in the NS5 region of HCV genome (Flasuviricetes: Amarillovirales: Flaviviridae: Hepacivirus C) in samples obtained in 2022-2023 from HIV-infected treatment-naive residents of Altai Krai (PubMed, Vopr Virusol) - "Our results may indirectly indicate the increasing proportion of the HCV subtype 3a in the hepatitis C epidemic in the Altai Territory. Our data on DR and polymorphisms should be taken into account in antiviral therapy of patients."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

SOFOSBUVIR BASED REGIMENS ARE EFFECTIVE FOR HEPATITIS C TREATMENT IN PATIENTS WITH END-STAGE RENAL DISEASE IN REAL-LIFE SETTING (AASLD 2025) - "Sofosbuvir in combination with daclatasvir or velpatasvir are highly and equally effective against HCV in CKD patients with eGFR below 30 mL/min."

Clinical • Chronic Kidney Disease • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

IN VITRO MODEL OF AURKB EXPRESSION LEVELS REGULATION MEDIATED BY SOFOSBUVIR TREATMENT (AASLD 2025) - " Cultures of Huh7 and Huh7.5 hepatoma cell lines were treated with SOF (C22H29N3FO9P) or daclatasvir (DCV) (BMS-790052) at different doses...All SOF-induced effects were reversed in the presence of AZD1152, an inhibitor of AURKB activity, confirming that they were exerted through the AURKB pathway... These results suggest that SOF can induce cell cycle modifications through AURKB activation in in vitro cell models. The effect of these changes in vivo (hepatitis C patients treated with SOF) should be analysed, taking into account that HCV eradication may induce an increase in AURKB per se, due to the inhibitory effect that the viral core protein exerts on AURKB activity."

Preclinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Solid Tumor • AURKB • DUSP1 • EGFR • PDGFRB

Assessment of direct-acting antiviral treatment outcomes in patients with chronic hepatitis C infected with various HCV genotypes: Insights from a real-world cohort in West Bengal, India. (PubMed, BMC Infect Dis) - "This study highlights genotype-specific variations in treatment response, with GT-3b exhibiting lower treatment response which highlights the need to decipher the reasons behind treatment failure for future therapeutic management."

Journal • Real-world evidence • Retrospective data • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Smartphone-assisted EY@ MOF-5-based dual-emission fluorescent sensor for rapid on-site detection of daclatasvir and nitenpyram (ACS-Fall 2025) - "Then, a smartphone-integrated sensing system is introduced for on-site, real-time, and quantitative analysis of DCT and NTP. The smartphone-assisted intelligent sensing method manifests promising results for DCT and NTP monitoring in biological and food samples, demonstrating its promising potential for the on-site detection of biologically and environmentally significant analytes."

Repurposing Daclatasvir for MASLD Therapy - A Promising Step Forward with Challenges Ahead. (PubMed, J Lipid Res) - No abstract available

Journal • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Impact of Resistance Associated Substitutions and Predictors of Treatment Failure Following Direct-acting Antiviral Therapy in a Viral Hepatitis C Elimination Cohort. (PubMed, J Clin Exp Hepatol) - P=N/A | "The National Viral Hepatitis Control Program (NVHCP) has a cure rate of 91.6% when using direct-acting antivirals (DAAs)-sofosbuvir with an NS5A inhibitor (ledipasvir, daclatasvir or velpatasvir) ± ribavirin in the Punjab hub-and-spoke model of hepatitis C virus (HCV) elimination...Among these Y93K, L30R, G30 H/R confer resistance to velpatasvir; such patients received retreatment with voxilaprevir-containing regimens...RAS do not appear to be a primary factor for treatment failure in a public health setting. NCT03488485 available from https://clinicaltrials.gov/study/NCT03488485."

Journal • Fibrosis • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation

Sensitive RP-HPLC method with fluorimetric detection for concurrent quantification of emtricitabine, Daclatasvir and Ledipasvir in human urine. (PubMed, Sci Rep) - "Stability assays reveal that the three studied drugs were stable during preparation, injection and storage. The method can be applied for the quantification of the three drugs co-administered to HIV/HCV co-infected patients' urine which aids in therapeutic drug monitoring and dosage adjustment for chronic patients."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments (ERA 2025) - "From 2015 to 2020, patients received the following DAA protocols: Sofosbuvir + either Simeprevir, Daclatasvir, Ledipasvir, or Ribavirin. Relapsing cases were associated with more aggressive clinical and pathological renal manifestations. Membranoproliferative & Crescentic GN were the most common glomerular lesions in relapsing cases."

Complement-mediated Rare Disorders • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Nephrology • Pain • Renal Disease • Rheumatology • Vasculitis

Hepatoprotective drug screening identifies daclatasvir a promising therapeutic candidate for MASLD by targeting PLIN2. (PubMed, J Lipid Res) - "The specific mutation at the binding amino acid sites of PLIN2 with daclatasvir largely abolished the anti-MASH benefit of daclatasvir. In conclusion, the findings of our present study for the first time identified the anti-HCV drug daclatasvir as a novel and potent PLIN2 protein degradant for MASH protection."

Journal • Hepatology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Targeted Protein Degradation • PLIN2

Evaluating Antidiabetic Modulatory Effects on Drug-induced Pulmonary Arterial Hypertension Using Real-world Data (ATS 2025) - "Drugs included dasatinib, methamphetamine, thiotepa, carboplatin, busulfan, cyclophosphamide, sofosbuvir, ribavirin, daclatasvir, interferon beta-1a, and sertraline. Patients on GLP-1 and Biguanides presented a lower incidence of PAH and a longer (delayed) time-to-PAH when compared to controls. Longer time-to-PAH may indicate slower PAH progression and characterize the modulatory effects of antidiabetics. Understanding the differential outcomes and onset patterns in PAH could lead to novel combination therapies in the highly comorbid PAH landscape."

Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Metabolic Disorders • Pulmonary Arterial Hypertension • Respiratory Diseases

Autoimmune manifestations and direct-acting antiviral drugs in Egyptian patients with hepatitis C virus infection: A cohort study. (PubMed, J Int Med Res) - "All patients were treated with sofosbuvir (400 mg once daily) plus daclatasvir (60 mg once daily) for 3 months. In patients with sustained virologic response, autoimmune manifestations persisted in 66 of the 71 (92.9%) patients with an observable rise in posttreatment erythrocyte sedimentation rate and C-reactive protein level (p > 0.01). The predictors of persistence of autoimmune manifestation were age ≥49 years (p = 0.009), female sex (p = 0.026), and tobacco use (p = 0.043).ConclusionDirect-acting antiviral drugs were not associated with a significant short-term change in the prevalence of autoimmune manifestations in patients who had hepatitis C virus infection with sustained virologic response."

Journal • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Oncology • Rheumatology • Solid Tumor • CRP

Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study (EASL 2025) - "Most of the patients had been pre-treated with VEL/SOF (55%, 17/31), 13% (4/31) each had received G/P (glecaprevir/pibrentasvir) or GZR/EBR(grazoprevir/elbasvir)±SOF and 10% (3/31) each had been pretreated with LDV(ledipasvir)/SOF or DCV(daclatasvir)/SOF. The combination of G/P+SOF represents an effective third-line treatment option for difficult-to-treat patients, including those with cirrhosis, HCC, or HCV GT3 infection. These findings highlight the importance of tailored salvage therapy to achieve optimal outcomes in this challenging population."

Clinical • Real-world • Real-world evidence • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Hepatitis C treatment in arterial hypertension is safe and highly effective: real-world study (EASL 2025) - "The predictors of treatment failure in AH patients included genotype 3 infection, decompensated liver function, cirrhosis, thrombocytopenia, and treatment with asunaprevir+daclatasvir. Although hypertensive patients were more prone to therapy discontinuation, the vast majority of them completed it, with only one-fifth reporting adverse events, mostly fatigue. The study shows that DAAs therapy is safe and effective in hypertensive patients and underscores the need for targeted screening strategies, particularly in hypertensive individuals, to optimize treatment success and reduce the long- term burden of HCV in this population."

Clinical • Real-world • Real-world evidence • Anemia • Cardiovascular • Fatigue • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Liver Failure • Obesity • Oncology • Pulmonary Arterial Hypertension • Solid Tumor • Thrombocytopenia

The Genotypes/Subtypes and Antiviral Drug Resistance of the Hepatitis C Virus from Patients in a Tertiary Care Hospital in Nepal. (PubMed, Viruses) - "Resistant mutations against sofosbuvir, pibrentasvir, velpatasvir, daclatasvir, and dasabuvir were found at 25%, 18%, 16%, 16%, and 2%, respectively, mostly on subtype 3a. The predominant HCV genotype/subtype in our patient group was 3a, and resistance mutations against direct-acting antivirals were found in most untreated patients."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

A key role for hepatitis C virus NS5A serine 225 phosphorylation revealed by super-resolution microscopy. (PubMed, Sci Rep) - "Although S225 phosphorylation was not specifically affected by treatment with the NS5A-targeting direct acting antiviral agent daclatasvir, this resulted in the condensation of NS5A-positive punctae into larger structures, recapitulating the S225A phenotype. These data are consistent with a key role for S225 phosphorylation in the regulation of NS5A function."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Therapeutic potential of Solanum surattense against hepatitis C virus in liver hepatoma cells. (PubMed, Pak J Pharm Sci) - "Data shows that the leaf extract effectively inhibited HCV-3a replication by 62% and 84% at 50µg/mL and 100µg/mL concentrations, respectively, compared to the control daclatasvir, which reduced HCV replication by 70% at 100 nM (p<0.000)...In addition, both herbal extracts showed HepG2 cytotoxicity. The findings suggest that S. surattense may be a better HCV and HCC inhibitor and requires further study."

Journal • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Liver Cancer • Solid Tumor

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. (PubMed, BMJ Open Gastroenterol) - "The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

EARLY NONINVASIVE EVALUATION OF LIVER FIBROSIS AFTER HEPATITIS C TREATMENT: THE IMPACT OF INFLAMMATION. (PubMed, Arq Gastroenterol) - "The evaluation of hepatic elastography by the ARFI method before and after (6 - 9 months) successive treatment of hepatitis C in responders and non-responders led to the conclusion that the reduction of elastography parameters seems to be related to a decrease in hepatic inflammation rather than a reduction in fibrosis per se."

Journal • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study. (PubMed, J Clin Med) - " A cross-sectional study was conducted including 375 HCV patients with different genotypes, treated using different DAA regimens, with or without ribavirin, between January 2012 and December 2020 at the Sultan Qaboos University Hospital and the medical city for military and security services, two tertiary hospitals in Muscat, Oman...No significant adverse effects were reported. Based on our real-world experience, DAAs are highly effective in treating patients with HCV infection in Oman, with an excellent tolerability and safety profile."

Clinical • Journal • Real-world • Real-world evidence • Fibrosis • Gastroenterology • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor

Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis. (PubMed, Expert Opin Drug Saf) - "Among them, rituximab (231 cases) was associated with the highest number of cases of HBV-R. According to the disproportionality analysis, the top five drugs with the highest ROR and PRR were daklinza, vocabria, doxorubicin, sovaldi, and ribavirin...Through an analysis of the FAERS database, it was observed that some pharmaceuticals do not adequately address the risk of HBV-R in their drug documentation. These findings could assist healthcare providers in promptly recognizing drug-induced HBV-R."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure • Oncology